Corvus Pharmaceuticals, Inc.
CRVS
$3.24
$0.010.31%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 19.99% | 15.90% | 3.54% | -2.89% | -9.41% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 18.08% | 7.99% | -22.04% | -26.15% | -27.05% |
| Operating Income | -18.08% | -7.99% | 22.04% | 26.15% | 27.05% |
| Income Before Tax | -130.47% | -88.24% | 42.04% | 39.20% | 34.57% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -130.47% | -88.24% | 42.04% | 39.20% | 34.57% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -130.47% | -88.24% | 42.04% | 39.20% | 34.57% |
| EBIT | -18.08% | -7.99% | 22.04% | 26.15% | 27.05% |
| EBITDA | -18.49% | -8.60% | 21.64% | 25.72% | 26.68% |
| EPS Basic | -71.53% | -44.87% | 46.63% | 41.77% | 36.41% |
| Normalized Basic EPS | -71.51% | -44.73% | 46.66% | 41.79% | 36.44% |
| EPS Diluted | -71.53% | -44.26% | 46.80% | 41.95% | 36.61% |
| Normalized Diluted EPS | -71.51% | -44.73% | 46.66% | 41.79% | 36.44% |
| Average Basic Shares Outstanding | 26.94% | 18.41% | 10.47% | 4.47% | 3.14% |
| Average Diluted Shares Outstanding | 26.94% | 18.41% | 10.47% | 4.47% | 3.14% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |